| Title |
Effect of Treating Psoriasis on Cardiovascular Co-Morbidities: Focus on TNF Inhibitors
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, November 2013
|
| DOI | 10.1007/s40257-013-0052-6 |
| Pubmed ID | |
| Authors |
Shannon Famenini, Eric Y. Sako, Jashin J. Wu |
| Abstract |
Psoriasis patients are at increased risk for cardiovascular disease. Literature on rheumatoid arthritis has shown the association of treatment with tumor necrosis factor (TNF) inhibitors and improvement of cardiovascular disease. Recent literature has also shown similar findings in psoriasis patients. We present a review of the literature on the effect of TNF inhibitors for psoriasis treatment on cardiovascular disease, cardiovascular biomarkers, and insulin resistance. We conclude that TNF inhibitors may be especially beneficial in preventing myocardial infarction, to a degree greater than methotrexate, especially in the Caucasian population. The effects of TNF inhibitors in altering insulin sensitivity or preventing new onset diabetes have been contradictory. Case reports of both hyperglycemia and hypoglycemia developing in patients under TNF inhibitor treatment teach us to warn patients about these side effects. More robust clinical studies are needed to evaluate the true effect of TNF inhibitors in diabetic psoriasis patients. More studies are also needed to assess the effect of TNF inhibitors on hypertension, dyslipidemia, and stroke. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 19% |
| Other | 6 | 14% |
| Student > Ph. D. Student | 6 | 14% |
| Student > Doctoral Student | 4 | 9% |
| Researcher | 4 | 9% |
| Other | 10 | 23% |
| Unknown | 5 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 53% |
| Nursing and Health Professions | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Unspecified | 2 | 5% |
| Other | 3 | 7% |
| Unknown | 6 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2014.
All research outputs
#18,384,336
of 22,771,140 outputs
Outputs from American Journal of Clinical Dermatology
#860
of 975 outputs
Outputs of similar age
#231,789
of 306,652 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#7
of 7 outputs
Altmetric has tracked 22,771,140 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 975 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,652 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.